Suppr超能文献

一种包含中性粒细胞与淋巴细胞比值的新列线图的开发,用于预测接受经动脉化疗栓塞的肝细胞癌患者的生存情况。

Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

作者信息

Chon Young Eun, Park Hana, Hyun Hye Kyung, Ha Yeonjung, Kim Mi Na, Kim Beom Kyung, Lee Joo Ho, Kim Seung Up, Kim Do Young, Ahn Sang Hoon, Hwang Seong Gyu, Han Kwang-Hyub, Rim Kyu Sung, Park Jun Yong

机构信息

Department of Internal Medicine, Institute of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.

CHA Bundang Liver Center, CHA Bundang Hospital, Seongnam 13496, Korea.

出版信息

Cancers (Basel). 2019 Apr 10;11(4):509. doi: 10.3390/cancers11040509.

Abstract

The neutrophil-to-lymphocyte ratio (NLR) has recently been reported to predict the prognosis of hepatocellular carcinoma (HCC). We explored whether NLR predicted the survival of patients with HCC undergoing transarterial chemoembolization (TACE), and developed a predictive model. In total, 1697 patients with HCC undergoing TACE as first-line therapy at two university hospitals were enrolled (derivation set n = 921, internal validation set n = 395, external validation set n = 381). The tumor size, tumor number, AFP level, vascular invasion, Child-Pugh score, objective response after TACE, and NLR, selected as predictors of overall survival (OS) via multivariate Cox's regression model, were incorporated into a 14-point risk prediction model (SNAVCORN score). The time-dependent areas under the receiver-operating characteristic curves for OS at 1, 3, and 5 years predicted by the SNAVCORN score were 0.812, 0.734, and 0.700 in the derivation set. Patients were stratified into three risk groups by SNAVCORN score (low, 0-4; intermediate, 5-9; high, 10-14). Compared with the low-risk group, the intermediate-risk (HR 3.10, < 0.001) and high-risk (HR 7.37, < 0.001) groups exhibited significantly greater mortality. The prognostic performance of the SNAVCORN score including NLR in patients with HCC treated with TACE was remarkable, much better than those of the conventional scores. The SNAVCORN score will guide future HCC treatment decisions.

摘要

最近有报道称中性粒细胞与淋巴细胞比值(NLR)可预测肝细胞癌(HCC)的预后。我们探讨了NLR是否能预测接受经动脉化疗栓塞术(TACE)的HCC患者的生存情况,并建立了一个预测模型。共有1697例在两家大学医院接受TACE作为一线治疗的HCC患者入组(推导集n = 921,内部验证集n = 395,外部验证集n = 381)。通过多变量Cox回归模型选择肿瘤大小、肿瘤数量、甲胎蛋白水平、血管侵犯、Child-Pugh评分、TACE后的客观反应以及NLR作为总生存期(OS)的预测指标,并将其纳入一个14分的风险预测模型(SNAVCORN评分)。在推导集中,SNAVCORN评分预测的1年、3年和5年OS的受试者工作特征曲线下的时间依赖性面积分别为0.812、0.734和0.700。根据SNAVCORN评分将患者分为三个风险组(低风险,0 - 4分;中风险,5 - 9分;高风险,10 - 14分)。与低风险组相比,中风险组(HR 3.10,< 0.001)和高风险组(HR 7.37,< 0.001)的死亡率显著更高。在接受TACE治疗的HCC患者中,包含NLR的SNAVCORN评分的预后性能显著,远优于传统评分。SNAVCORN评分将指导未来HCC的治疗决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7711/6520830/f38c785b51c6/cancers-11-00509-g001.jpg

相似文献

5
A Novel Neutrophil-to-Lymphocyte Ratio and Sarcopenia Based TACE-Predict Model of Hepatocellular Carcinoma Patients.
J Hepatocell Carcinoma. 2023 Apr 20;10:659-671. doi: 10.2147/JHC.S407646. eCollection 2023.

引用本文的文献

2
Current research status of transarterial therapies for hepatocellular carcinoma.
World J Gastrointest Oncol. 2024 Sep 15;16(9):3752-3760. doi: 10.4251/wjgo.v16.i9.3752.
3
Which is the best TACE agent for patients with different NLR hepatocellular carcinomas? A systematic review and network meta-analysis.
Heliyon. 2024 May 4;10(9):e30759. doi: 10.1016/j.heliyon.2024.e30759. eCollection 2024 May 15.
4
A Deep Learning Model Combining Multimodal Factors to Predict the Overall Survival of Transarterial Chemoembolization.
J Hepatocell Carcinoma. 2024 Feb 26;11:385-397. doi: 10.2147/JHC.S443660. eCollection 2024.
5
Immune Effects of Intra-Arterial Liver-Directed Therapies.
J Vasc Interv Radiol. 2024 Feb;35(2):178-184. doi: 10.1016/j.jvir.2023.10.019.
6
Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure.
J Liver Cancer. 2020 Mar;20(1):72-77. doi: 10.17998/jlc.20.1.72. Epub 2020 Mar 31.
7
Establishment and validation of a novel prognostic model for non-virus-related hepatocellular carcinoma.
Cancer Cell Int. 2022 Oct 2;22(1):300. doi: 10.1186/s12935-022-02725-5.
8
The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma.
Ther Adv Med Oncol. 2022 Jul 16;14:17588359221113266. doi: 10.1177/17588359221113266. eCollection 2022.
9
An ALBI- and Ascites-Based Model to Predict Survival for BCLC Stage B Hepatocellular Carcinoma.
Evid Based Complement Alternat Med. 2022 Jul 7;2022:1801230. doi: 10.1155/2022/1801230. eCollection 2022.

本文引用的文献

2
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
3
Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review.
J Clin Transl Hepatol. 2018 Mar 28;6(1):69-78. doi: 10.14218/JCTH.2017.00031. Epub 2017 Dec 17.
4
Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance.
Aliment Pharmacol Ther. 2018 Apr;47(8):1201-1212. doi: 10.1111/apt.14578. Epub 2018 Feb 28.
6
Epidemiology of liver cancer in South Korea.
Clin Mol Hepatol. 2018 Mar;24(1):1-9. doi: 10.3350/cmh.2017.0112. Epub 2017 Dec 18.
7
Treatment options after sorafenib failure in patients with hepatocellular carcinoma.
Clin Mol Hepatol. 2017 Dec;23(4):273-279. doi: 10.3350/cmh.2017.0108. Epub 2017 Nov 20.
8
Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
Clin Mol Hepatol. 2017 Dec;23(4):265-272. doi: 10.3350/cmh.2017.0111. Epub 2017 Nov 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验